Treatment Information

Back

Rectal Cancer treatment details. Biologic therapy.

Albert-Ludwigs-University, Freiburg, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:4City/State/Province:Freiburg
Treatments:Biologic therapyHospital:Albert-Ludwigs-University
Drugs:Journal:Link
Date:Jun 2005

Description:

Patients: This Phase I/II study involved 27 patients with metastatic colorectal cancer (23) or breast cancer (3). All patients but one had confirmed liver metastasis. Fifteen patients were men and twelve were women. The median age was 58.

Treatment: The treatment consisted of one biological agent: PTK/ZK. PTK/ZK is a multiple VEGF receptor inhibitor. Since VEGF signaling is essential for tumor growth and metastasis, PTK/ZK was considered to have therapeutic potential.

Toxicity: Grade 3-4 toxicities included hypertension, vertigo, ataxia, dyspnea, nausea, and vomiting.

Results: The median overall survival was 11.8 months.

Support: The work was supported by Schering AG, Berlin and the study was done in collaboration with Novartis Pharmaceuticals Corporation. These two companies are involved in marketing PTK/ZK.

Correspondence: Klaus Mross, MD




Back